Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

Dr. Tolaney, Associate Director, Susan F. Smith Center for Women's Cancers, Director, Clinical Trials, Breast Oncology, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, provides an overview of the results from the SOPHIA trial, a Phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab and 1-3 lines of prior treatment